The efficacy of adalimumab in the treatment of  hidradenitis suppurativa
The efficacy of adalimumab in the treatment of  hidradenitis suppurativa
Yazar: Balevi, Ali; Ustuner, Pelin; Özdemir, Mustafa
Dergi: Dicle Tıp Dergisi, Vol. 45 No. 1, 2018
Anahtar kelimeler: Health Care Administration ; Sağlık Kurumları Yönetimi ; Adalimumab,eccrine glands

Objectives:  Hidradenitis  suppurativa  is  seen  as  a  result  of  the  occlusion,  constriction  and  bacterial  infection  of  the apocrine  glands  in  bilateral  axillas,  submammarian  areas,  neck,  inguinal  regions,  flexural  surfaces  of  the  thighs  and anogenital areas. Among the biological agents adalimumab is a recombinant human IgG1 monoclonal antibody; TNF-α antagonist approved to be used in the treatment of hidradenitissuppurativa.  Methods: In this study, 12 patients resistant to conventional treatments with moderate severity, Hurley stage 2 or 3 were started subcutaneous adalimumab treatment. The disease activities upon the hidradenitis suppurativa, clinical severity index and life quality index of the patients were examined both before and 1 year after the treatment.  Results: Twelve  patients were recruited. In the examination of  the  hidradenitis  suppurativa  clinical  severity  scores, significant  clinical  responses  were  noted  in  9  (75%)  patients.  While  the  mean  value  of  the  life  quality  index  was 14.4±6.9 before the treatment, it was determined to be significantly decreased to 4.3±3.8 after the treatment. Conclusion:  We  concluded  that  adalimumab;  the  unique  biological  agent  approved  to  be  used  in  the  treatment  of treatment-resistant, moderate-severe hidradenitis suppurativa is efficient and safe in similar ratios with the previous clinical studies in the literature.

Objectives:  Hidradenitis  suppurativa  is  seen  as  a  result  of  the  occlusion,  constriction  and  bacterial  infection  of  the apocrine  glands  in  bilateral  axillas,  submammarian  areas,  neck,  inguinal  regions,  flexural  surfaces  of  the  thighs  and anogenital areas. Among the biological agents adalimumab is a recombinant human IgG1 monoclonal antibody; TNF-α antagonist approved to be used in the treatment of hidradenitissuppurativa.  Methods: In this study, 12 patients resistant to conventional treatments with moderate severity, Hurley stage 2 or 3 were started subcutaneous adalimumab treatment. The disease activities upon the hidradenitis suppurativa, clinical severity index and life quality index of the patients were examined both before and 1 year after the treatment.  Results: Twelve  patients were recruited. In the examination of  the  hidradenitis  suppurativa  clinical  severity  scores, significant  clinical  responses  were  noted  in  9  (75%)  patients.  While  the  mean  value  of  the  life  quality  index  was 14.4±6.9 before the treatment, it was determined to be significantly decreased to 4.3±3.8 after the treatment. Conclusion:  We  concluded  that  adalimumab;  the  unique  biological  agent  approved  to  be  used  in  the  treatment  of treatment-resistant, moderate-severe hidradenitis suppurativa is efficient and safe in similar ratios with the previous clinical studies in the literature.